TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02634463

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: No study agent will be administered as a part of this study. Participants must be on Aripiprazole 5 milligram (mg) (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (300-400 mg once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for development of antipsychotic immunoassays.

Intervention type: OTHER
Group type: OTHER
Intervention: Olanzapine
Description: No study agent will be administered as a part of this study. Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.

Intervention type: DRUG
Group type: OTHER
Intervention: Paliperidone
Description: No study agent will be administered as a part of this study. Participants must be on Paliperidone 3 mg (minimum dose) to 12 mg (maximum dose), orally, daily or long-acting injectable versions (25-150 mg equivalent \[eq.\] once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.

Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone
Description: No study agent will be administered as a part of this study. Participants must be on Risperidone 1 mg (minimum dose) to 8 mg (maximum dose), orally, daily or long-acting injectable versions (12.5-50 mg once every 2 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
Study: NCT03969095

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tongue Pressure Resistance Training
Description: 2 supervised sessions per week: Each session will be a maximum of one hour in length and will include: 1) 20 repetitions of maximum isometric presses (MIPs) with rapid rise in pressure at the anterior location. 2) 15 regular saliva swallows with the IOPI bulb in place. 3)15 effortful saliva swallows with the IOPI bulb in place. 4) 10 generalization tasks with mildly thick liquid and IOPI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tongue Pressure Resistance Training
Description: 2 supervised sessions per week: Each session will be a maximum of one hour in length and will include: 1) 20 repetitions of maximum isometric presses (MIPs) with rapid rise in pressure at the anterior location. 2) 15 regular saliva swallows with the IOPI bulb in place. 3)15 effortful saliva swallows with the IOPI bulb in place. 4) 10 generalization tasks with mildly thick liquid and IOPI.
Study: NCT01311882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4305 40 mg
Description: 4 x 10 mg MK-4305 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4305 20 mg
Description: 2 x 10 mg MK-4305 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zopiclone
Description: 1 x 7.5 mg Zopiclone tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grossly Matching Placebo for Zopiclone
Description: Grossly Matching Placebo for Zopiclone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grossly Matching Placebo for Zopiclone
Description: Grossly Matching Placebo for Zopiclone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grossly Matching Placebo for Zopiclone
Description: Grossly Matching Placebo for Zopiclone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo for MK-4305
Description: Matching Placebo for MK-4305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for MK-4305
Description: Matching Placebo for MK-4305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo for MK-4305
Description: Matching Placebo for MK-4305
Study: NCT01393275

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation exercise intervention
Description: exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 60 minutes rehabilitation exercise training - once a week~15 minutes warm up, 30 minutes strength endurance training - once a week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo control group
Description: exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 5 minutes walking 55 minutes conversation in the group- once a week~15 minutes warm up, 30 minutes strength endurance training - once a week
Study: NCT01392547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: 1-3 doses per bleeding episode

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptacog alfa (activated)
Description: 1-3 doses per bleeding episode
Study: NCT02736201

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Capacitive diathermy (T-CaRe®)
Description: The instrumental manual therapy with the switched on capacitive diathermy electrode (IMT+ T-CaRe® on; n = 10) and the instrumental manual therapy with the switched off capacitive diathermy electrode (IMT+ T-CaRe® off; n = 10) will be bilaterally treated for 4 weeks (1 treatment per week during 10 minutes) in the lumbopelvic region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capacitive diathermy (T-CaRe®)
Description: The instrumental manual therapy with the switched on capacitive diathermy electrode (IMT+ T-CaRe® on; n = 10) and the instrumental manual therapy with the switched off capacitive diathermy electrode (IMT+ T-CaRe® off; n = 10) will be bilaterally treated for 4 weeks (1 treatment per week during 10 minutes) in the lumbopelvic region.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Instrumental manual therapy
Description: Bilateral longitudinal massage in the lumbar region (110 mm; 5 minutes in each side)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrumental manual therapy
Description: Bilateral longitudinal massage in the lumbar region (110 mm; 5 minutes in each side)
Study: NCT00587717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Two 80 mg pills simvastatin taken 24 hours prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: take 2 80 mg pills placebo 24 hours prior to surgery
Study: NCT03780335

Intervention type: DIAGNOSTIC_TEST
Intervention: Computation of quantitative flow ratio
Description: Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computation of quantitative flow ratio
Description: Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
Study: NCT02492178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrarectal artesunate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrarectal artesunate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous quinine
Study: NCT00766363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
Study: NCT02492178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous quinine
Study: NCT00925834

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal suggestions
Description: Verbal suggestions of a vasodilatory effect on cardiac vessels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal suggestions
Description: Verbal suggestions of a vasodilatory effect on cardiac vessels

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Verbal suggestions
Description: Verbal suggestions of a vasodilatory effect on cardiac vessels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal suggestions
Description: Verbal suggestions of a vasodilatory effect on cardiac vessels
Study: NCT04206735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interprofessional Education (IPE)
Description: We will use the training stated in the arm description above. In addition, prerecorded webinars that include evidence-based practice management of COPD will be released every month for the champions and clinicians to watch at their leisure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care of patients hospitalized with severe COPD exacerbation
Study: NCT00881738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg Tablets (Geneva, USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)
Study: NCT03793348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCD
Description: Micro coring skin removal with automated coring device
Study: NCT03414775

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nourish
Description: The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediasure
Description: The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
Study: NCT04496739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer Educational Materials
Description: Receive educational materials about breast cancer risk and chemoprevention via RealRisk

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Educational Materials
Description: Receive educational materials about breast cancer risk and chemoprevention via RealRisk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Given patient-centered decision support via an action plan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Given decision support and action plans based on patient's interactions with RealRisks via the BNAV support tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in audio-recorded interview via telephone or video conference

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01229189

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Maternal dose of 4000 IU daily for 20 weeks Neonatal dose of 400 IU daily for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplemented to pregnant women and their neonates in the same pattern as in intervention group.
Study: NCT02213835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate diet (SCD)
Study: NCT03554382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: system to support self-management of hypertension
Description: The patients are provided with a home BP monitor. Thereafter they will be asked to use the self-management support system and self-report, once daily in the evening, via their own mobile phone during eight weeks. At each occasion, the patients first answer the questions on wellbeing, symptoms, lifestyle, medication intake and side effects and then measure their BP and pulse, and when these data (mean of three readings) are input into the mobile phone, they automatically register in the database. During intervention the paient has regular access to self-reported data via graphs
Study: NCT02953522

Intervention type: OTHER
Group type: OTHER
Intervention: 191 mcg/day of Folate
Description: Diet containing 191 mcg / day of Folate

Intervention type: OTHER
Group type: OTHER
Intervention: 90 mcg / day of Folate
Description: Diet containing 90 mcg / day of Folate
Study: NCT02436525

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional stainless steel orthodontic brackets ligated with stainless steel ligature (Oromco - USA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: passive self-ligating stainless steel orthodontic brackets (Oromco - USA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active self-ligating stainless steel orthodontic brackets (Oromco - USA)
Study: NCT00792012

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Intensity-Modulated Radiation Therapy
Description: All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.
Study: NCT00981097

Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
Study: NCT02476786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT-B
Description: The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Archived tissue collection
Study: NCT00766363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivastigmine
Description: Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
Study: NCT04137159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation rowing exercise
Description: Full-body aerobic exercise
Study: NCT00768079

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: A single dose of benralizumab (MEDI-563) 0.3 or 1 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: A single dose of benralizumab (MEDI-563) 0.3 or 1 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
Study: NCT00417105

Intervention type: PROCEDURE
Intervention: hemodialysis
Description: group 1: twice weekly, four hours

Intervention type: PROCEDURE
Intervention: hemodialysis
Description: group 2: twice weekly, eight hours
Study: NCT02619760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-month DAPT
Description: 1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12-month DAPT
Description: 12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
Study: NCT04480840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03416855

Intervention type: DRUG
Intervention: Insulin degludec /insulin aspart
Description: Commercially available Insulin degludec /insulin aspart (Ryzodeg® FlexTouch®) according to routine clinical practice at the discretion of the treating physician.
Study: NCT03742765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentivizing planning
Description: Participants receive bonus incentives for planning their workouts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentivizing exercise
Description: Participants receive bonus incentives for exercising
Study: NCT01556399

Intervention type: OTHER
Intervention: Tissue Sampling
Description: A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.
Study: NCT01432405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Type 2 diabetic subjects will be randomized to receive exenatide 10 micrograms injected subcutaneously twice daily for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Type 2 diabetic subjects will be randomized to receive pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Type 2 diabetic subjects will be randomized to receive pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
Study: NCT00417105

Intervention type: PROCEDURE
Intervention: hemodialysis
Description: group 3: every other day, eight hours

Intervention type: PROCEDURE
Intervention: hemodialysis
Description: group 4: six days a week, eight hours
Study: NCT03870347

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic ultrasound
Description: Upper endoscopy using an echoendoscope to obtain ultrasound images of the pancreaticobiliary system and adjacent structures.
Study: NCT03460691

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Bariatric surgery will done to the patients who were morbid obesity
Study: NCT00940732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Destigmatisation and Mental Health Literacy
Description: Written material delivered over 2 weeks via the Internet, including mythbusters, debunking common myths around anxiety and depression, as well information about a range of celebrities who have identified themselves as having depression or anxiety. Also contains mental health literacy information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Help-seeking list
Description: List of sources for mental health help-seeking delivered over 2 weeks.
Study: NCT02147886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabaletta for IV infusion once weekly during 24 weeks
Description: Cabaletta for IV infusion once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabaletta for IV infusion once weekly during 24 weeks